Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) is dated September 12, 2023. The report addresses a critical regulatory event regarding the Company's listing status on the Nasdaq Capital Market and provides preliminary updates on its liquidity position and recent equity financing activities.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $6.7 million as of September 12, 2023 (preliminary and unaudited).
- Recent Equity Financing: Between May 4, 2023, and September 8, 2023, the Company raised approximately $12.9 million in net proceeds through the sale of 50,837,984 shares under an At-The-Market (ATM) Sales Agreement with Oppenheimer & Co. Inc.
- Post-Reporting Sales: Subsequent to September 8, 2023, the Company sold an additional 16,149,321 shares for net proceeds of approximately $1.8 million (settlement pending).
- Shares Outstanding: 62,870,563 shares as of September 12, 2023 (reflecting activity through September 8).
- Stock Price: The closing bid price was $0.10 or less for ten consecutive trading days ending September 11, 2023.
Material Changes and Listing Status
The Company received a Staff Delisting Determination from Nasdaq on September 12, 2023, due to failure to meet the "Low Priced Stock Rule" (closing bid price of $0.10 or less for ten consecutive days). This determination follows a prior notice on August 8, 2023, regarding non-compliance with the minimum $1.00 bid price requirement and the $35 million Market Value of Listed Securities (MVLS) requirement.
While the Company has until February 5, 2024, to regain compliance with the Bid Price and MVLS rules, the immediate delisting determination requires an appeal. Trading is currently stayed pending the appeal process.
Outlook, Management Commentary, and Risks
- Appeal Process: The Company intends to request a hearing before a Nasdaq Hearings Panel by September 19, 2023. Hearings are typically scheduled 30 to 45 days after the request.
- Remediation Strategy: Management is considering a reverse stock split to increase the share price and regain compliance with the Bid Price Rule. However, the filing states no assurances can be given regarding the undertaking or effectiveness of such a split.
- Continued Listing: The Company's stock will continue to trade on Nasdaq under the symbol "AVTX" while the appeal is pending.
- Future Compliance: Even if the appeal is successful, the Company must still achieve an MVLS of $35 million for ten consecutive business days by February 5, 2024.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearings Panel appeal, expected to be decided 30-45 days after the September 19, 2023 deadline.
- Confirm whether the Company executes a reverse stock split and the specific ratio if approved.
- Monitor the Market Value of Listed Securities (MVLS) to ensure it reaches $35 million before the February 5, 2024 deadline.
- Review the final audited financial statements to confirm the preliminary $6.7 million cash balance.
- Track the settlement of the $1.8 million in post-September 8 stock sales to update liquidity figures.